Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper compounded versions ...

The Food and Drug Administration said on Friday that the shortage of semaglutide injection products, such as Novo Nordisk's Wegovy, has been resolved. FDA's update led to renewed uncertainty for a ...

On Friday, shares of Hims&Hers Health Inc (NYSE:HIMS) dropped over 20% following an FDA announcement that the supply shortage of Novo Nordisk (NYSE:NVO)'s weight loss and diabetes drugs was ending.

American doctors, who tracked over 37 million people, said the injections put users at higher risk of nonarteritic ischemic anterior optic neuropathy (NAION).

American doctors, who tracked over 37 million people, said the injections put users at higher risk of nonarteritic ischemic ...

More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.

Two Omaha women lost more than 300 lbs. combined with injections of a GLP-1 drug, which are used increasingly for weight loss ...

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

A randomized, placebo-controlled trial validates a side effect frequently observed by doctors and patients. A new study from ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday.

The semaglutide shortage has officially ended in the US—which means the GLP-1 drug industry is about to undergo massive changes.